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Experimental model of lead nephropathy. I. Continuous high.dose lead
administration. This study followed the progression of lead nephrop-
athy in male Sprague-Dawley rats (E) administered lead acetate (0.5%)
continuously in drinking water for periods ranging from Ito 12 months.
Control animals (C) were pair-fed. Observations included renal pathol-
ogy by light and electron microscopy, Wet and dry kidney weights, and
glomerular filtration rate (GFR) to assess renal function. Urinary
excretion of lead, the enzymes N-acetyl-beta-D-glucosaminidase
(NAG) and glutathione-S-transferase (GST), and brush border antigens
(BB5O, CG9, and HF5) were utilized to explore possible markers of
kidney injury. GFR was increased significantly after three months of
lead exposure, but was decreased significantly after 12 months. Kidney
wet weights were significantly greater in E than C from three months
on. Kidney dry weight/wet weight ratio was constant up to three
months, but decreased in E at 12 months. Glomerular diameters were
normal at all time periods; the nephromegaly was related primarily to
hypertrophy of proximal tubules. Lead inclusion bodies were found in
nuclei of proximal convoluted tubules and pars recta at all times.
Tubular atrophy and interstitial fibrosis first appeared at six months,
and increased in severity thereafter. Brush borders of proximal tubules
were disrupted at one and three months, but recovered thereafter.
Focal and segmental glomerulosclerosis was observed in 2 of 10 rats at
12 months. Arteries and arterioles remained normal at all time periods.
Urinary NAG was elevated in E above C after three months of lead
exposure. However, urinary NAG in C also increased with age,
obscuring changes in the 12 month E rats. GST was elevated after three
months of lead administration in E, riot without an attendant age-related
increase in C rats. in three-month E rats, urinary brush border antigens
were increased above C, but were decreased at six and 12 months,
correlating with the morphologic changes in brush border. We conclude
that a high dose of lead in rats may initially stimulate both renal cortical
hypertrophy and an increase in GFR. Later, the adverse effects of lead
on the tubulointerstitium predominate, and GFR falls. The urinary
marker, NAG, was abnormal in the early stages of the disease, but
age-related changes obscured its utility at later stages; urinary GST
appeared to be a more consistent marker of injury.
Lead nephropathy in industrial workers was previously con-
sidered to be a rare disorder in the United States, although a
significant prevalence of overt lead nephropathy was reported
from Europe [1, 2]. Largely through studies by Wedeen and
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associates [31, the incidence of subclinical nephropathy in
American lead workers is now estimated to be as high as 16%.
Further, an analysis of 153 bone biopsies from dialyses of
end-stage renal patients in three European countries disclosed
that approximately 5% of these patients had elevated bone lead,
with values comparable to those seen in industrially-exposed
populations [41. Thus, the contribution of lead nephropathy to
the population of end-stage renal disease may be appreciable.
Insight as to the pathogenesis of lead nephropathy has been
provided by observations in an experimental rat model by
Goyer [5]. Goyer has emphasized that the proximal tubule
nuclear inclusion body, long recognized as a hallmark of lead
nephropathy [61, is a complex of lead and lead-binding protein
and serves to sequester lead in a non-toxic form. Nuclear
inclusion bodies are prominent early in the course of the
nephropathy, but decrease in number and size with continuing
lead exposure; simultaneously, tubules become atrophied and
tubulointerstitial fibrosis progresses. Eventually the kidneys
show glomerulosclerosis and renal function becomes impaired
[5]. Parallel findings have been described by Cramer et al in a
biopsy study of lead-exposed workers [7]. Workers with less
than one-year lead exposure showed typical lead-induced intra-
nuclear inclusion bodies but biopsies were otherwise normal on
light microscopy. Workers with from 4 to 30 or more years lead
exposure did not demonstrate nuclear inclusion bodies but their
biopsies revealed abnormal amounts of peritubular and intersti-
tial fibrous tissue.
In the absence of clearance measurements, early detection of
this disorder has not been possible, since most of the usual
markers of kidney disease (for example, albuminuria, beta-2-
microglobulinuria and urine sediment changes) are not present
until late stages of the disease [3, 8]. Changes in blood sub-
stances which reflect alterations in glomerular filtration rate,
such as serum creatinine and serum urea nitrogen (SUN), also
appear to be insensitive indices of renal dysfunction in individ-
ual workers [3, 9]. Epidemiological studies, however, indicate
that there is a positive correlation between both serum creati-
nine and SUN with length of exposure to lead, even after
correction for age-related changes [10].
This study followed the pathological progression of lead
nephropathy as well as measures of renal function in a rat model
produced by continuous high dose lead administration. Urinary
enzymes, tubular brush border antigens and urinary lead were
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followed as possible early indicators of lead-induced nephro-
toxicity.
Materials
Animals
Five experimental groups of 12 male Sprague-Dawley rats
each, with age-matched pair-fed controls, were fed a semi-
purified low-calcium diet (Composition of diet: 27% purified
casein; 39% sucrose; 19% cornstarch; 10% cottonseed oil; 4%
salt mix U.S.P. XIV, purchased from ICN Biochemicals,
Cleveland, Ohio) as described by Mylorie et al [11]. Rats were
weighed before entering into the study and again at the time of
sacrifice. Beginning at two months of age the five experimental
groups were given 0.5% lead acetate in their drinking water.
Durations of lead exposure periods for experimental groups
were 1, 3, 6, 9, and 12 months, respectively. For the groups
receiving lead acetate for 9 and 12 months, dosage was reduced
at six months from 0.5% to 0.1% for the remainder of the
experimental period to decrease mortality due to anemia and
central nervous system effects.
Collection of urine and blood
Two days prior to sacrifice, rats were placed in individual
metabolic cages during the day and urine samples were col-
lected in plastic tubes placed on ice. Urine samples were
centrifuged and aliquots (1 ml) were removed and frozen at
—80°C until required.
Blood was drawn from the femoral artery in a heparinized
syringe. Red blood cells were separated from plasma by cen-
trifugation at 3000 rpml4°C for 10 minutes. Serum samples were
used for determination of serum creatinine and SUN concen-
trations. A portion of the whole blood (1 ml) was frozen at
—80°C for determination of lead content.
Determination of glomerular filtration rate (GFR)
Indirect assessment of GFR was made by measuring serum
true creatinine chromogen according to the method of Polar and
Metcoff [12], in which a strong cation exchange resin (Dowex
W-X8, Sigma Chemical Co., St. Louis, Missouri, USA) was
used for rapidly absorbing and desorbing true creatinine from
plasma of rats. The absorbed material was then assayed accord-
ing to the methods of Hare [13] and Lauson [14].
A more precise measure of GFR was made using a modified
plasma isotope clearance technique described by Bryan, Jar-
chow and Maher [15]. Rats were injected with '251-iothalamate
(15 Ci/rat; specific activity 1.1 mCi) in tail arteries. Animals
were kept conscious in a restrainer for 40 to 60 minutes and
were then given an intraperitoneal injection of anaesthetic (90
mg/kg Ketalar and 10 mg/kg Rompun). Rats were weighed and
blood was drawn from femoral artery in a heparinized syringe;
the elapsed time following injection of isotope was noted
precisely. Red blood cells were separated from the serum by
centrifugation and 100 l of serum was counted for radioactivity
in an Abbot gamma counter. Residual radioactivity in the
syringe utilized for injection of '251-iothalamate was also mea-
sured in order to permit calculation of the absolute amount of
injected isotope. Clearances were expressed as ml/min/lOO g
body weight, calculated from the following formulae:
C'IOT = V ln (P0/P)It
where V equals distribution volume of iothalamate (determined
to be 26.9 1.7 percent of body weight in the rat); P,, =
theoretical plasma iothalamate concentration at the time of
injection = I/V (where I is the amount of iothalamate injected);
= the observed iothalamate concentration at t minutes after
injection and ClOT is the plasma decay of iothalamate.
Renal clearance (GFR) = C'IOT — 0.34
Measurement of urinary markers
Urine creatinine was measured colorimetrically according to
the method of Bonsnes and Taussky 116]. Urinary N-acetyl-
beta-D-glucosaminidase (NAG) was measured using the ni-
trostyryl substrate described by Yuen et al [17]. Ligandin
(glutathione-S-transferase; GST) concentration in urine was
assessed by concentrating the urine 20-fold and measuring the
rate of conjugation of chlorodinitrobenzene to the free sulfhy-
dryl group of reduced glutathione [18]. Brush border antigens in
urine were measured immunologically by the ELISA technique
as described by Mutti et a! [19]. The antigen, BB5O, reflects
diffuse distribution in the rat's kidney, HF5 reflects arteriolar
myocytes and CG9 reflects brush border only. All determina-
tions were expressed as units/g creatinine.
Determination of lead in blood and urine
Lead contents of whole blood and urine were measured using
an atomic absorption spectrophotometer (Perkin Elmer, model
#305 with graphite furnace). Whole blood lead values were
expressed as tg/dl and urine lead as tg/g creatinine.
Preparation of kidney tissues
After removal of blood, kidneys were excised quickly and
placed on ice. Whole kidneys were weighed ("wet weight"),
cortex was separated from medulla, wrapped in aluminum foil
and stored at —80°C. A piece of cortex (approximately 0.5 g)
was weighed, placed on a glass plate, dried in an oven at 70°C
for 24 hours and its weight determined ("dry weight").
Pathology
Sections of the cortex were placed in appropriate fixatives for
processing for light, electron and immunofluorescence micro-
scopies using standard methods [20]. The semi-thin sections
stained with toluidine blue from the tissue fixed in glutaralde-
hyde and embedded in plastic provided the best preparation for
light microscopic evaluation. Some sections were also stained
with periodic acid-methenamine silver.
For each of the important abnormalities, a semiquantitative
assessment of the severity (including extent of damage, fre-
quency of certain changes) graded from 0 to 4+ was estab-
lished. Those parameters evaluated included presence and
frequency of intranuclear inclusion bodies, degree of tubular
atrophy with accompanying interstitial fibrosis, presence of and
percent involvement with segmental glomerulosclerosis, and
ultrastructural cell morphology. Glomerular diameters, includ-
ing both capillary tuft and Bowman's spaces, were measured
using an eyepiece micrometer and standard techniques [21]. For
each animal, twenty-five consecutive glomeruli were measured.
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Table 1. Body and kidney weight of animals
Groups
Weight of animats g Weight of kidney g Kidney
dry/wet weightStart Final Wet Dry
I Month E
C
226 10
226 17
272 19
281 15
1.78 0.19
1.63 0.09
0.40 0.03
0.39 0.03
0.22
0.24
3 Months E
C
229 8
224 9
283 15
316 18
2.16 0.39a
1.69 0.17
0.43 0.09
0.31 0.08
0.20
0.18
6 Months E
C
217 8
213 7
483 62
585 45
2.32 0,41b
1.56 0.22
ND
ND
9 Months E
C
218 7
220 9
594 40
642 78
2.50 0.39"
1.63 0.19
ND
ND
12 Months E
C
216 13
216 11
642 66
754 123
2.84 041b
1.92 0.25
0.55 0.07
0.54 0.07
0.19a
0.28
The data represent the mean so. Abbreviations are E, experimental rats; C, control rats; ND, not determined.
a P < 0.05 when compared to control
ID p < 0.001 when compared to control
Statistical treatment of data
Statistical analyses of the data were performed using the
paired t-test. Results are expressed as mean standard devia-
tion. Statistical significance for t-test and ANCOVA was as-
sessed using a two-tailed probability level of 0.05, and comput-
ing was conducted using the 3V program in the Biomedical
Computer Programs (BMDP) [22].
Results
Animal growth
All animals were entered into the study weighing approxi-
mately 220 g (Table 1). Both experimental and control rats
gained weight throughout the study, but despite pair-feeding,
the experimental groups weighed less than their matched con-
trols at the time of sacrifice (Table 1).
Kidney weight
Wet weight of kidneys from control animals did not change
significantly during the study (Table 1). Kidney wet weights
from experimental animals increased with the duration of
exposure to lead and were significantly different from their
matched controls at 3, 6, 9 and 12 months. There was no
detectable change in the kidney dry weight of one-month
experimental animals when compared to controls. Dry weight
of experimental animals at three months was increased when
compared to their controls, while the ratio of dry weight to wet
weight was the same at one month and three months, suggesting
that the alterations in kidney wet weight were related to
increased kidney tissue mass rather than to edema (Table 1). At
12 months the kidney dry weight of experimental animals was
the same as that of controls, while the dry weight to wet weight
ratio was significantly decreased.
Blood and urine lead
Blood lead values after one month of lead administration
reached 45.5 21.9 /.Lg/dl and gradually increased to 125.4
10.1 g/dl after six months (Fig. 1). At this time, to avoid
anemia and central nervous system disturbances in the animals
due to high blood lead levels, the lead acetate in their drinking
water was reduced to 0.1%. Reduction of lead concentration in
drinking water resulted in lower blood lead values in 9 and 12
Duration of exposure, months
Fig. 1. Blood lead concentration in experimental and control rats at
various time periods. Open and closed bars represent blood lead in
experimental and control rats, respectively. In this figure and in
subsequent figures, values are expressed as mean SD.
month old rats (Fig. 1). Urine lead values for lead-treated rats
were also significantly elevated above control at all exposure
times, markedly fluctuating during the study (Fig. 2), but
remaining above 100 xg/g creatinine throughout.
GFR
There was no difference in GFR of rats treated with lead for
one month as compared to their age-matched, pair-fed controls
(Fig. 3). GFR was increased significantly after three months of
exposure to lead (experimental, 1.00 0.14 vs. control, 0.83
0.26 ml/min/l00 g body wt; P 0.05), but was decreased
significantly after 12 months of lead administration (experimen-
tal, 0.78 0.16 vs. control, 0.96 0,08 ml/min/lOO g body
weight; P < 0.01). Serum true creatinine chromogen showed
similar trends. Serum creatinine in experimental animals was
lower than normal controls at three months (experimental, 1.05
0.16 vs. control, 1.24 0.26 mg/dl; P <0.05), and higher than
normal controls at six months (experimental, 1.96 0.33 vs.
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Fig. 3. Changes in GFR of experimental and control animals with
duration of exposure to lead. Open and closed bars represent GFR in
experimental and control rats, respectively.
Pathology
Characteristic intranuclear inclusions were present in some
cells of proximal convoluted tubules and pars recta in all
lead-treated animals from one month onward. Their frequency
and size increased with duration of exposure to lead up to six
months of exposure; thereafter, size, and to a lesser degree,
numbers, of intranuclear inclusions decreased. Nevertheless,
nuclear inclusion bodies continued to be present in the majority
of proximal tubular cells at 12 months (Fig. 9, Table 2). The
inclusions were easier to detect by electron microscopy, but
were also identified in all animals by light microscopy (Fig. 10).
Enlargement of proximal tubule cells and their nuclei was first
evident at three months; these changes persisted throughout the
study. It was not possible to ascertain whether these changes
were applicable to the entire proximal tubule or to segments
thereof. At six months focal tubular atrophy and interstitial
fibrosis first appeared, then increased in extent throughout the
remainder of the experiment (Table 2, Fig. 11 A and B). This
was a focal process. Variable numbers of lymphocytes and
plasma cells were in areas of fibrosis. Enlarged and cystically
dilated tubules were present in four experimental animals at 12
months (Fig. 11C). Of the nine control animals, four had tubular
atrophy and interstitial fibrosis with scattered lymphocytes of a
mild to moderate degree at twelve months. Renal tumors were
observed in two out of nine lead-treated animals at nine months
but in none at 12 months. At one and three months, brush
border structures of experimental animals were abnormal.
There was disruption of the luminal aspects of most cells in
each affected tubule profile; this was manifested primarily by
simplification of the surface with reduced numbers of microvilli
or prominently swollen microvilli (Fig. 12). It was not possible
to ascertain if all proximal cells of a single nephron were
affected. By six months, improvement in brush border morphol-
ogy was evident; closely packed microvilli once again appeared
in some, but not all, cells. This appearance persisted for the
remainder of the experiment. From six months onwards, nor-
mal microvilli were present in cells with intranuclear inclusion
bodies as well as those without inclusions (Fig. 13A). Abnormal
0
1 3 6 9 12
Duration of exposure, months
Fig. 2. Urine lead concentration in experimental and control rats at
various time periods. Open and closed bars represent urine lead in
experimental and control rats, respectively.
control, 1.59 0.19; P < 0.001). At later time periods, no
significant differences in serum creatinine were noted between
experimental and control rats. Within the first six months of
lead exposure, blood lead and GFR were positively correlated
in the experimental animals (r = 0.703, P < 0.001; Fig. 4). A
plot of the ratio of GFR to wet weight of kidneys was biphasic
in experimental animals, rising to a maximum at six months and
thereafter falling, whereas the ratio of GFR to wet weight of
kidneys in normal rats reached a maximum at six months and
remained constant thereafter (Fig. 5).
Urinary markers
Urinary NAG was elevated above control after three, six,
and nine months of lead exposure (Fig. 6). Urinary NAG in
control animals also increased with age, obscuring the differ-
ence at 12 months between experimental rats and their controls.
Figure 7 depicts changes in urinary GST with time of exposure
to lead. GST was elevated after three months, six months and
12 months of lead administration, but differences between
experimental and controls at nine months did not reach a level
of significance. Results of the mean of individual changes in
urinary brush border antigens (BB5O, HF5 and CG9) are shown
in Figure 8. When mean values of each of the three brush border
antigens were examined statistically, no significant differences
were observed between experimentals and controls at any of
the time periods, However, as each experimental animal had its
own pair-fed control, the results were recalculated as differ-
ences between individual experimental and control animals and
expressed as the mean of individual changes, that is, a delta
value. There was no change in the delta concentration of all
three antigens after one month of exposure to lead, but all three
increased significantly after three months of treatment with
lead. The pattern of changes was reversed at six and 12 months,
showing decreased delta concentration of all three brush border
antigens in the urine of experimental animals.
microvilli were present predominantly in cells with intranuclear
inclusions (Figs. 9A, 12 and 13B).
At one month, mitochondrial abnormalities were evident in
the lead-treated animals. The mitochondria were more rounded
than elongated and displayed irregular and angulated arrange-
ment of cristae. These derangements persisted throughout the
period of observation, but were more intense at one and three
months of evaluation (Fig. 14). OrgandIes other than mitochon-
dna were also often abnormal. Cisternae of endoplasmic retic-
ulum were dilated. Irregular lysosomes containing dense mate-
rial, some of which had a laminated appearance, were
numerous in many cells. Both of these lesions were most
Fig. 4. Correlation between GFR and blood
lead during the first six months cf lead
exposure.
noticeable in one- and three-month treated animals, diminishing
in frequency and severity in animals treated for longer periods
of time. However, these changes did not completely disappear
and were evident in a few cells after one year of lead adminis-
tration.
Glomeruli were structurally unchanged in all animals through
nine months of lead administration. Specifically there was no
difference in glomerular diameters between experimental and
control groups at any time during the study. At 12 months, two
of the ten experimental animals had focal and segmental gb-
meruloscierosis (Fig. 15). This light microscopic lesion was
associated with almost complete effacement of podocyte foot
processes as observed ultrastructurally. Epithelial cells were
separated from basement membranes by zones of pale-staining
new basement membrane material in sclerotic segments. There
were no electron dense deposits of immune complex type and
0 15 30 45 60 75 90 105 120 135 150
Blood lead, zg/dl
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immunofluorescence findings were negative. Focal and segmen-
tal sclerosis was absent in all control animals. A few completely
sclerotic glomeruli were evident at 9 and 12 months in the
majority of lead-treated animals and at 9 and 12 months in a few
control animals. There were no abnormalities in arteries or
arterioles at any time during the 12 months of observation.
Discussion
In this communication we have described a rat model of
continuous lead exposure over varying periods of time, at
exposure levels comparable to those which occurred in earlier
years in the lead industry, when high blood leads were common
[23]. In adults, continuous occupational lead exposure can lead
to a slow, progressive, chronic renal failure which is only
partially reversible [9]. Prior experimental models of lead
nephropathy have demonstrated that the severity of the renal
lesion depends in part on the animal species [24, 251, and on
duration and level of exposure [24—26]. Revis, Shaw and Bull
[251 found that at a relatively low dose of lead exposure
(0.02%), pigeons were much more susceptible to the nephro-
toxic effects of lead than mice or rats. Vyskocil et al [241 found
that rats given 2% lead acetate in their drinking water for two
months developed pathological changes in their kidneys asso-
ciated with increased urinary excretion of /32-microglobulin,
glucose, total proteins, lysozyme and lactic dehydrogenase
(LDH). In contrast, rats given 0.5% lead acetate for two months
showed no histological or renal functional changes while rats
given 1% lead acetate for three months showed proximal
tubular alterations associated only with /32-microglobulinuria.
Fowler et al [27] found that rats exposed to low doses of lead
(0.005% and 0.025%) for nine months developed proximal
tubular changes consisting of intranuclear inclusion bodies,
swollen dysfunctional mitochondria, and numerous electron-
dense lysosomes, but no interstitial fibrosis.
The classical description of the progressive renal disease
produced by continuous high dose (1% lead acetate) lead
exposure in rats was provided by Goyer and colleagues [51.
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Fig. 8. Age-corrected changes in brush border antigens with duration
of exposure to lead. * P < 0.05; ** P < 0.001.
Young adult rats given 1% lead acetate in drinking water
developed, in the first 10 weeks, cytoplasmic cloudy swelling
and intranuclear inclusion bodies in proximal tubular cells,
together with ultrastructural and functional changes in mito-
chondria. Between 10 and 20 weeks, there was increasing
dysplasia of proximal tubular cells, most severe in the pars
recta. Continued lead-feeding resulted in atrophy of tubular
lining cells, tubular dilation and interstitial fibrosis. As tubular
atrophy and scarring progressed, the number of intranuclear
inclusion bodies decreased. Finally, rats fed lead for more than
a year developed progressively severe interstitial scarring, and,
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Fig. 7. Changes in urinary ligand (GST) in experimental and control
rats at various time periods. Open and closed bars represent ligand in
experimental and control rats, respectively.
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Fig. 9. Proximal tubular nuclear inclusion bodies in lead-treated rats. A. At 3 months, the inclusion is large and has a large densely-staining central
core and a relatively small outer fibrillary zone. The apical portions of this proximal tubular cell lack the brush border (x3780). B. At 12 months.
Most bodies (arrow) at this time had reduced fibrillary zones, as noted here (x 13,900).
Table 2. Pathological changes in lead treated rats
Group
Tubular Glomerular deposits
nuclear Interstitial and segmental
inclusions fibrosis sclerosis
lMonth E
C
3 Months E
C
6 Months E
C
9 Months E
C
12 Months E
C
3+ 0 0
0 0 0
3+ 1+ 0
0 0 0
3+ 1+ 0
0 0 0
2—3 + 2—3 + 0
0 0 0
2—3+ 4-1- 1—2+
0 1—2+ 0
Scale is 0 to 4+ . Abbreviations are: E, experimental rats; C, control
rats.
in some, sclerotic glomeruli and renal tumors were found.
Various dietary factors play a role in determining absorption of
lead as well as adverse effects of lead on the kidney (28).
Mylorie et al [11] described a diet low in calcium which
exaggerated the nephrotoxic effect of lead. The more rapid
progression of renal disease seen in our model than in that of
Goyer, who employed higher dosages of lead (1%), may be
attributable to our use of the Mylorie diet, as blood lead levels
in our model were comparable to blood leads reported by Goyer
[51.
In our rat model, an increase in GFR was noted at three
months, which was paralleled by an increase in the wet and dry
weights of the kidneys, reflecting hypertrophy of total kidney
mass. Goyer [51 also observed increased kidney wet weight in
rats given a high dose of lead for protracted periods of time,
while O'Flaherty et al [29] observed increases in both kidney
wet weight and dry weight in rats given varying doses of lead.
O'Flaherty et al [29] also observed significantly increased
para-aminohippurate (PAH) clearance and marginally increased
GFR at four months in rats given 0.55% lead in drinking water.
In our model of lead nephropathy, we did not document
glomerular hypertrophy at three months; the increased kidney
weight appeared to relate predominantly to hypertrophy of
proximal tubules. The direct correlation between blood lead
and GFR over the first six months suggests that lead directly or
indirectly (that is, via systemic or local humoral substances)
stimulated hyperfiltration as well as tubular hypertrophy. These
observations in rats are supported by recent human studies by
Hu [30], who reported that middle-aged adults (ages 49 to 60),
with prior well-documented childhood lead poisoning, had
significantly higher creatinine clearances than age-matched
control subjects.
GFR and kidney dry weight and kidney wet weight increased
in parallel over the first three months, indicative of tissue
hypertrophy. However, by 12 months, GFR had decreased and
extensive tubular atrophy and dilatation as well as tissue
fibrosis were present. At this time, although kidney wet weight
in experimental animals remained above controls, the ratio of
dry weight to wet weight was significantly decreased. Thus
increased water content rather than tissue hypertrophy was the
primary reason for kidney enlargement at 12 months.
The exact sequence of events leading to selective hypertro-
phy of the proximal tubules after lead exposure must remain
speculative. However, it is apparent that deposition of lead is
localized predominantly to the proximal tubule, as evidenced
by the restriction of the high lead-containing nuclear inclusion
bodies to this segment of the nephron [5]. In addition, it is
known from studies by Choie and Richter [311 that increased
protein synthesis occurs within the renal cortex in response to
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Fig. 10. Comparison of cortical tubules in
control and three month lead-treated rats. A.
Control rat at three-months (periodic acid-
methenamine silver x240). B. Lead-treated rat
at three months. The tubular cells and profiles
are larger; numerous intranuclear inclusions
are evident (periodic acid-methenamine silver
x240).
Fig. 11. Sequential tubulointerstitial changes. A. Lead-treated rat at six months. There is mild tubular atrophy with focal interstitial fibrosis(arrow) (Toluidine blue x 120). B. Lead-treated rat at twelve months. There is more extensive interstitial fibrosis and tubular atrophy (toluidine
blue x 120). C. Lead-treated rat at twelve months. A cystically-dilated proximal tubule is evident (toluidine blue >< 120).
lead. Therefore the kidney hypertrophy (that is, increased dry protein synthesis has also been documented in isolated tubules
weight) observed during the first three months of lead adminis- exposed to ammonium chloride [32, 331.
tration may be related to this increased protein synthesis, Focal and segmental glomeruloscierosis was documented in
Proximal tubular hypertrophy as a consequence of increased only 20% of the experimental animals at 12 months. This is in
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Fig. 12. Disruption of proximal tubular brush border in lead-treated
rat at one month. An irregularly-shaped intranuclear inclusion is
present. The luminal surface of the cell lacks a complete brush border
(arrow) (x5760).
contrast to other experimental models of renal disease (such as,
diabetic nephropathy [34] and partial ablation [35], which are
characterized initially by hyperfiltration, and subsequently by
the regular appearance of focal and segmental glomeruloscie-
rosis. The absence of vascular changes in our experimental
model differentiates it from human lead-related [36] or non-lead-
related [37, 38] gouty nephropathy, in which arterial and
arteriolar sclerosis are prominent [39], and which may contrib-
ute to the progressive renal scarring through ischemia. Pure
lead nephropathy in rats may represent an unusual form of renal
disease in which early hyperfiltration and proximal tubular
hypertrophy do not regularly lead to glomerular focal sclerosis
but instead to tubular atrophy and interstitial fibrosis, resulting
in progressive loss of renal function. Although the present study
does not directly address the mechanism by which renal func-
tion is lost, Mackenson et al [40] have suggested in other forms
of interstitial nephritis that collagen deposition in the intersti-
tium compresses intertubular capillaries, thus increasing post-
glomerular flow resistance and eventually impeding glomerular
filtration. Sequential changes in preglomerular and glomerular
hemodynamic factors, in particular the ratio of systemic and
local renal vasodilating to renal vasoconstrictirig substances,
may also have participated in the early increase in glomerular
filtration rate as well as the later decrease.
Nuclear inclusion bodies were seen in all lead-treated ani-
mals, and were present in some, but not all tubules, from one
month onward. Although, as previously reported by Goyer [5],
there was a diminution in the size and number of nuclear
inclusion bodies as tubulointerstitial disease progressed be-
tween six and 12 months, there was no association between the
presence or absence of nuclear inclusion bodies in a given cell
and the degree of organelle disruption in that cell. This obser-
vation does not necessarily negate Goyer's suggestion that
lead-binding proteins play a protective role against lead toxicity
in the kidney [28], as there are lead-binding proteins in rat
kidney cytosol [41] which cannot be visualized as discrete
bodies.
Both the diagnosis of lead nephropathy in patients with renal
disease of unknown etiology and the detection of early lead
nephrotoxicity in workers with defined lead exposure are
difficult. Albuminuria is not seen in early stages of lead
nephropathy and, therefore, detection of lead nephrotoxicity in
lead workers depends on the finding of elevated serum creati-
nine and SUN, both relatively insensitive indices of GFR.
Several urinary enzymes, derived from renal tubular cytoplasm
or proximal tubular brush border, have been proposed as
indicators of early tubular injury. These have included lactic
dehydrogenase, alkaline phosphatase, lysozyme, beta glue-
uronidase and others [42, 43]. One lysosomal enzyme,
N-acetyl-beta-D-glucosaminidase (NAG), has been accepted as
a useful clinical marker of tubular injury [44]. Wellwood et al
[44] found that urinary NAG increased with age but the enzyme
levels were significantly above the age-matched normal values
in various acute and chronic renal diseases such as acute
glomerulonephritis, chronic pyelonephritis and chronic glomer-
ulonephritis, as well as in acute tubular injury such as ischemic
acute tubular necrosis and kidney transplant rejection. Meyer et
at [45] also investigated urinary NAG levels in workers exposed
to lead, mercury and various organic chemicals and found that
NAG levels were elevated in 7 of 29 lead workers. Coratelli et
al [461 examined 20 normotensive battery workers who were
occupationally exposed to lead dust for time periods ranging
from 0.6 to 17 years in order to evaluate, by means of enzy-
muria, the early tubular injury caused by lead. Mean urinary
excretLon of NAG and lysozyme were increased in the exposed
workers when evaluated on five separate occasions over 12
months. After removal from occupational exposure for one
month, the battery workers showed a significant decrease in the
urinary excretion of NAG, but not in excretion of lysozyme.
Ligandin (glutathione-S-transferase, GST), a soluble protein
found in the proximal tubule of the kidney, has proved to be a
useful marker of chemically-induced tubular damage, particu-
larly in the S3 segment of the proximal tubule [181. Feinfeld,
Bourgoignie and Fleischner [18] showed that GST was consis-
tently released into the urine of rats after injection with mercu-
ric chloride, which preferentially injures the S3 segment of the
proximal tubule. Experimental studies in lead poisoned rats
have demonstrated that the S3 segment of the proximal tubule
is most susceptible to lead injury, possibly because fewer of the
"protective" nuclear lead inclusion bodies are seen here than in
the SI and S2 segments [471.
Non-enzymatic markers of tubular injury, brush border anti-
gens in urine, have also proved to be useful in detecting metal
toxicity in the kidney [191 as well as tubular injury caused by
other nephrotoxins, such as hydrocarbons [481. Mutti and
co-workers [49, 501 developed monoclonal antibodies to three
proximal tubular brush border proteins (BB5O, HF5 and CG9).
They have found that the urine of patients treated with cis-
platinum showed up to a 50-fold increase in the brush border
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Fig. 13. Relationship of microvilli abnormalities to presence or absence of nuclear inclusion bodies. A. Proximal tubular cell from lead-treated rat
at nine months. The microvilli are normal. Note complex intranuclear inclusion body (x7125). B. Proximal tubular cell from lead-treated rat at nine
months (><6250). The microvilli are irregularly formed, of varying lengths and widely separated. Note typical intranuclear inclusion. Compare
microvilli with those in Figures 9A and 12.
protein, BB5O (with estimated molecular weight of 50,000
daltons), as compared to normal controls.
Of the various urinary markers that were examined in this
study, urinary ligandin appeared to be the most accurate
predictor of subsequent renal damage. Urinary levels of this
enzyme were increased from three months onward, correlating
with the onset of pathological changes in the tubulointerstitium,
Furthermore, urinary ligandin was not elevated in animals
exposed to lower levels of lead (0.01%) for 12 months, who
showed no evidence for progressive renal damage 1511. NAG
was an overly sensitive, non-specific index of renal injury.
Age-related increases in the normal animal controls (previously
observed also in human populations) [44] obscured changes in
the older lead-treated rats, In addition, urinary NAG was
elevated over controls during the initial nine months of low lead
exposure, despite the absence of significant pathological
changes [51]. Urinary brush border antigens increased early in
the course of development of the renal lesion, coinciding with
the hyperfiltration period, but decreased subsequently, presum-
ably related to improvement in brush border morphology. Mutti
[52] has emphasized previously that increased urinary excretion
of brush border antigens occurs only in the presence of "ac-
tive" tubular lesions.
Urine lead concentration has been used in the past as an
indicator of differing levels of lead toxicity. Gibson, MacKenzie
and Goldberg [53], however, reported that urinary lead values
in three groups of lead-exposed workers (blood leads ranging
from 52 to 84 g/dl) did not differ significantly from each other
and were independent of any clinical symptoms. Others [54]
have also reported that occupationally exposed workers with
blood leads between 40 and 120 g/dl had urinary lead values
that consistently exceeded 100 tg/g creatinine. Positive corre-
lations have been found between indicators of lead toxicity
[urinary coproporphyrins and urinary delta-aminolevulinic
(ALA)] and urinary lead [53]. The above findings suggest the
possibility that urine lead, like urine cadmium [55], might
represent a kidney saturation threshold caused by reaching a
tubular maximum for reabsorption of the metal or by shedding
of the metal into the urine associated with tubular destruction.
In the present study, urinary lead was consistently increased
above 100 ig/g creatinine in all of the experimental animals.
Whether this change reflected an increased body burden of lead
or an early, rather subtle, adverse effect of lead on tubular
function cannot be determined with any certainty. Future
observations on animals and industrial workers exposed to
a
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Fig. 15. Glomerulus from lead-treated rat at twelve months. There is a
well-defined segment of sclerosis (arrow); the remainder of the glomer-
ulus is unremarkable. Note also numerous intranuclear inclusions in
cells of proximal tubules (arrow heads) (toluidine blue x200).
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Fig. 14. Abnormal mitochondria in lead-treated rat at one month.
Mitochondria are swollen and rounded instead of elongated. The cristae
are shortened and lack normal interdigitating pattern (x 17,400).
lower doses of lead will be needed to provide a more definitive
answer.
It should be emphasized that the present study examined the
effect of relatively high doses of lead, and was designed to
produce blood lead levels approximating or exceeding the 80
rg/dl blood level which was considered to be the acceptable
upper limit of industrial exposure until 1978 [23J, at which time
the Occupational Safety and Health Administration (OSHA)
mandated a progressive reduction in the blood lead levels of
industrial workers to the present cutoff of 40 g/dl. As sug-
gested by studies of Lilis et al [56], workers with lower lead
exposure may not have the same risk for developing renal
disease. Examination of the effects of low lead exposure on the
development of renal disease and dysfunction will be the
subject of a separate communication.
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